Piramal eyes M&A to rebuild pharma business; Lilly advances rollout of Alzheimer's imaging agent;

 @FiercePharma: Abbott unveils exec team to back up pharma spinoff CEO Richard Gonzalez--Dow JonesMore | Follow @FiercePharma

> India's Piramal Healthcare, which sold off its drug formulations business to Abbott Laboratories ($ABT) in 2010, has decided to get back into the business and has set up an M&A team to look for good buys. Report

> The radioactive diagnostic agent Amyvid, used in diagnosing Alzheimer's disease, is now being distributed by Eli Lilly ($LLY), which is also offering training on how to handle the highly sensitive agent. News

> Another court ruling is directing the FDA to do something about getting widespread use of antibiotics out of large-scale food production to limit the development of drug resistant superbugs. Story

> In an effort to be more self-sufficient in drugmaking, India intends to reduce its dependence on drugs and APIs manufactured in China. Article

> Plans for Teva Pharmaceutical's ($TEVA) $300 million, 1.1 million square-foot warehouse and IT center in Philadelphia appear to be floundering. Item

> A study released at the American Society of Clinical Oncology (ASCO) meeting found that Pfizer's ($PFE) Sutent and Bayer's Nexavar for adjuvant therapy are not apt to create significant cardiac toxicity in kidney cancer patients. More

Biotech News

 @FierceBiotech: Check out this special report by @MarkHFierce: Stem cell research advances in fits and starts. Report | Follow @FierceBiotech

 @JohnCFierce: Pazdur talks up the new wave of cancer drug apps (20) headed to the FDA this year. Expects rising number of approvals. More | Follow @JohnCFierce

 @RyanMFierce: My report on 5 next-gen software tools for biopharma R&D. Report | Follow @RyanMFierce

> Ceptaris Therapeutics raises $10M after FDA denial. News

> FDA foresees jump in apps for cancer drugs. Story

> BioInvent,ThromboGenics bloodthinner fails to beat Xarelto. More

> Targacept CEO exits after pipeline failures. Article

Medical Devices News

 @FierceMedDev: Only a few weeks left to submit your nominations for the 15 fiercest private device developers. Survey | Follow @FierceMedDev

> Biomet mulls dental division spin-off. Article

> Awarepoint snags $14M to expand RFIDs for hospitals. More

> Neuronetics gets CE mark for depression-treating device. Story

> Auxogyn reels in $18M to fuel IVF/embryo viability test. News

Biotech Research News

> Cellular changes explain greater breast cancer risk in older women. Story

> Novel technique helps detail Parkinson's modus operandi. Article

> U.K. scientists detect cancer from stray DNA fragments in blood. More

> Synthetic peptide helps defeat recurrent cancer's resistance to treatment. News

Pharma Manufacturing News

> Lipitor losses lead to Pfizer headcount reduction in Ireland. More

> FDA fails to send alerts on 20% of Class I drug recalls. Article

> Court says KV Pharma shareholders have every right to sue. Story

And Finally... An analysis of recent studies cast doubt on a highly publicized NIH study and indicate that women approaching menopause don't need to worry much about getting hormone-replacement therapy and that the benefits outweigh the risks for those suffering the most. Story